Researcher Resources
Who We Work With
Testimonials
Corrie Painter, PhD
Deputy Director, Count Me In
Broad Institute of MIT and Harvard
Working with the OSI has been one of the greatest honors of my professional career. As a sarcoma patient and as a cancer research scientist, I am committed to developing a comprehensive resource for the osteosarcoma community in order to drive discoveries and save lives. The sense of urgency that drives me is matched by everyone I’ve worked with at the OSI and I have faith that we will transform our understanding of this devastating disease.
Jonathan Bush, MD
Pediatric Pathologist, Department of
Pathology and Laboratory Medicine, University of British Columbia
Although unsuccessful in my first attempt, I received valuable and encouraging feedback that has prompted me to reach out to more collaborators and prepared a much more robust and exciting subsequent application.
Claudia Janda, PhD
Principal Investigator, Research Department at Princess Máxima Center for Pediatric Oncology
Although my proposed project was not funded, the application process was one of the most helpful and transparent I have observed. The feedback, to both for the LOI and the full applications, was very fair and helpful, and I really appreciate the time the committee took to think and comment on the project.
What We Fund
Clinical Trials
A clinical study with osteosarcoma patients is the culmination and ultimate test for often years of translational science work. We prioritize novel approaches that have strong preclinical rationales and utilize an innovative trial model that allows a rapid readout of effectiveness.
Correlative Science
Clinical trials are focused on determining whether an experimental therapy works so they usually do not include funding to study why the treatment does or does not work. Such correlative studies can add a valuable additional level of understanding to inform future development.
Preclinical/Translational Studies
Osteosarcoma is a complex, poorly understood cancer. We seek out projects that will generate seminal preclinical biological insights and suggest new ways to attack the disease.
High-Risk/High-Impact (New)
This new pilot grant program for the 2023-2024 Grant Cycle is for bold new ideas that may fall within any part of a drug development path, and that seek to deliver curative outcomes to patients with osteosarcoma.
2023-2024 Grant Cycle
The Osteosarcoma Institute is now accepting Letters of Intent (LOI) for the 2023-2024 Grant Cycle for Clinical Trials, Correlative Science, Preclinical/Translational, and High-Risk/High-Impact (new this year) grant programs. The LOI submission deadline is Wednesday, November 15th at 5:00pm EST. Invitations to submit a full proposal will be sent to applicants in January 2024, and grants will be awarded in Summer 2024. Please download the 2023-2024 OSI Grant Cycle Guidance document below that provides full details on the application process.
The OSI recognizes that not all projects are compatible with these time restrictions. Accordingly, we consider off-cycle proposals on a case-by-case basis. Additionally, the OSI has a Discretionary Grant Program for new and innovative ideas that need a relatively small, but timely investment to establish feasibility for further development in osteosarcoma. Please visit the OSI website here for more information on off-cycle and discretionary grant programs.
Thank you for giving hope to osteosarcoma patients and families. If you would like to be added to our researcher email list, please sign up as a “doctor or researcher” here. Additionally, you may follow our progress on Instagram, Facebook, Twitter, and LinkedIn.
Discretionary Grants
The OSI Strategic Advisoary Board members include physicians and basic science researchers who are continually introduced to innovative ideas and technologies at medical meetings and research conferences, or within the halls of their own institutions. If an intriguing idea is far enough along, its champion can be encouraged to apply for a grant from the OSI. But often times such an idea is in a nascent stage and needs a relatively small but timely investment to establish its feasibility for further development in osteosarcoma. The OSI has established a discretionary grant program to pursue these opportunities. On the spot grants of up to $20,000 can be nimbly authorized by committees of our SAB. To inquire about discretionary grants, please email a 1-2 page summary of your project to submissions@osinst.org.
Off-Cycle Requests
Our annual grant application window closes in mid-November. While our annual process constitutes the primary OSI grantmaking mechanism, we recognize that not all projects are compatible with that time frame; accordingly, we consider off-cycle proposals on a case-by-case basis. If you are interested in an off-cycle proposal, please contact us with a 1-2 page summary about your proposed project and include why it is time sensitive.